Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Shivani Baisiwala"'
Autor:
Shivani Baisiwala, Brenda Auffinger, Seamus P. Caragher, Jack M. Shireman, Riasat Ahsan, Gina Lee, Tanwir Hasan, Cheol Park, Miranda R. Saathoff, Anne C. Christensen, Atique U. Ahmed
Publikováno v:
Stem Cells International, Vol 2019 (2019)
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor affecting adults, with a median survival of approximately 21 months. One key factor underlying the limited efficacy of current treatment modalities is the remarkable p
Externí odkaz:
https://doaj.org/article/53050cd413d44260b9327fdb96bd5556
Autor:
Shivani Baisiwala, Myungjun Ko, Humza Zubair, Kevin Li, Andrew C. Vivas, Richard Everson, Linda Liau, Ausaf Bari, Kunal S. Patel
Publikováno v:
Journal of Neurosurgery: Case Lessons. 5
BACKGROUND Gliosarcoma is a rare and highly malignant cancer of the central nervous system with the ability to metastasize. Secondary gliosarcoma, or the evolution of a spindle cell–predominant tumor after the diagnosis of a World Health Organizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c8fde62c67c0098adf53a369064b704
https://doi.org/10.3171/case232
https://doi.org/10.3171/case232
Autor:
Ella N. Perrault, Jack M. Shireman, Eunus S. Ali, Peiyu Lin, Isabelle Preddy, Cheol Park, Shreya Budhiraja, Shivani Baisiwala, Karan Dixit, C. David James, Dieter H Heiland, Issam Ben-Sahra, Sebastian Pott, Anindita Basu, Jason Miska, Atique U. Ahmed
Publikováno v:
Science Advances. 9
During therapy, adaptations driven by cellular plasticity are partly responsible for driving the inevitable recurrence of glioblastoma (GBM). To investigate plasticity-induced adaptation during standard-of-care chemotherapy temozolomide (TMZ), we per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6e8d9d3ff35554531936929108a4623
https://doi.org/10.1126/sciadv.ade7236
https://doi.org/10.1126/sciadv.ade7236
Autor:
Khashayar Mozaffari, Amith Umesh, Anubhav Chandla, Mahlet Mekonnen, Brian Aguirre, Yelena Malkhasyan, Karam Han, Shivani Baisiwala, Adrian Murillo, Madhuri Wadehra, Isaac Yang
Publikováno v:
32nd Annual Meeting North American Skull Base Society.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a1a8bcdf8867eec572c92a1c5a89a32
https://doi.org/10.1055/s-0043-1762080
https://doi.org/10.1055/s-0043-1762080
Autor:
Chirag Goel, Shreya Budhiraja, Miranda R. Saathoff, Shivani Baisiwala, Atique Ahmed, Khizar Nandoliya
Publikováno v:
Stem Cell Rev Rep
Tumor invasion and metastasis remain the leading causes of mortality for patients with cancer despite current treatment strategies. In some cancer types, recurrence is considered inevitable due to the lack of effective anti-metastatic therapies. Rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf8031b3b206aef792bdffc0e2e308b5
https://doi.org/10.1007/s12015-021-10195-x
https://doi.org/10.1007/s12015-021-10195-x
Autor:
Shivani Baisiwala, Lu Sun, Benjamin Ellingson, Robert Prins, Phioanh L Nghiemphu, Timothy Cloughesy, Richard G Everson
Publikováno v:
Neuro-Oncology. 24:vii61-vii62
Neoadjuvant drug administration provides a window of opportunity for developing novel therapies. Specifically, neoadjuvant pembrolizumab (PD1 checkpoint inhibitor) has the potential for improving understanding of immunomodulatory effects on the tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4979c6d06152ef7f40bf52e3e50b697
https://doi.org/10.1093/neuonc/noac209.243
https://doi.org/10.1093/neuonc/noac209.243
Publikováno v:
Reference Module in Biomedical Sciences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cd5dc8aabc764200c98b9c48400a919
https://doi.org/10.1016/b978-0-12-820472-6.00062-1
https://doi.org/10.1016/b978-0-12-820472-6.00062-1
Autor:
Eunus S. Ali, Shreya Budhiraja, Charles David James, Ella Perrault, Anindita Basu, Luke Tomes, Sebastian Pott, Issam Ben-Sahra, Atique Ahmed, Andrew Zolp, Shivani Baisiwala, Peiyu Lin, Isabelle Preddy, Jack Shireman, Cheol Park
Glioblastoma (GBM) remains one of the most resistant and fatal forms of cancer. Previous studies have examined primary and recurrent GBM tumors, but it is difficult to study tumor evolution during therapy where resistance develops. To investigate thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8165007756b8f62ca40b6d1b8f2eb995
https://doi.org/10.1101/2021.11.23.469785
https://doi.org/10.1101/2021.11.23.469785
Autor:
Adam M. Sonabend, Li Chen, Shivani Baisiwala, Andrew Zolp, Khizar Nandoliya, Ella Perrault, Shreya Budhiraja, Cheol Park, Atique Ahmed, Crismita Dmello, Gabriel Dara
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is the most aggressive and common type of adult malignant brain tumor, with a median survival of only 21 months. To identify which genes drive its highly aggressive phenotype, we performed a genome-wide CRISPR-Cas9 knockout screen.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57f49de047a721f727a1c9143b7be6cb
https://europepmc.org/articles/PMC8598895/
https://europepmc.org/articles/PMC8598895/
Autor:
Crismita Dmello, Andrew Zolp, Gabriel Dara, Atique Ahmed, Shreya Budhiraja, Li Chen, Khizar Nandoliya, Adam M. Sonabend, Shivani Baisiwala, Cheol Park, Ella Perrault
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is the most common type of adult malignant brain tumor, with a median survival of only 21 months. This is partly due to the high rate of resistance to conventional therapy, including temozolomide (TMZ), leading to recurrence rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842887f94d868506b34ad3426ae2c5e7
https://europepmc.org/articles/PMC8598722/
https://europepmc.org/articles/PMC8598722/